Research for better outcomes

We're focused on discovering, developing and delivering novel medicines and treatment approaches that make a real impact for patients.

Investing in research

We aim for transformative change, not just incremental improvement. To do this, we invest in research to build new understanding and find genuinely novel solutions.

In 2019 we invested $5 billion into R&D. We are focused on areas of very high need and potential impact: immunology, oncology, neuroscience and virology.

Focusing on what matters most to patients

We know that the true value of a medicine is in the difference it makes in a patient’s everyday life. Our teams strive to bring a patient perspective into the lab as we develop innovative treatments, working to impact the outcomes that patients value most.

We work with patients and health care providers to understand the patient experience, define meaningful outcomes and determine how to best measure them.

Endometriosis: Looking back, demanding better

For women suffering from endometriosis pain, enough is enough. Learn how scientists, physicians and clinical trial specialists are challenging the status quo for this disease.

Read more

Improving disease management

Our health research goes beyond our medicine – we help advance the way diseases are managed. Some recent examples include:

Blood cancers
Some questions about disease management can’t be answered through a clinical trial. AbbVie has partnered with investigators from leading institutions around the world on the CLL Collaborative Study of Real-World Evidence (CORE). CORE collects detailed, real world longitudinal information about the experiences of CLL patients undergoing treatment, to help clinicians make more informed decisions in managing the disease.

Endometriosis affects an estimated 1 in 10 women of reproductive age, but diagnosis is often delayed. We partnered with patients and health care providers to create and validate the Painful Periods Screening Tool (PPST) to decrease the time to diagnosis for endometriosis.

Respiratory Syncytial Virus
RSV accounts for over 300,000 hospitalizations of children under age 5 in industrialized countries each year. Our team worked with health providers and statisticians to identify the most significant risk factors for RSV in preterm infants, with findings that help educate parents about risk and direct RSV preventive therapies to the most vulnerable infants.

Taking a holistic approach to improving health

Patients often need support in managing their treatment and condition. In the United States, our support programs help patients more fully understand their disease and the treatment they have been prescribed. AbbVie’s programs offer one-to-one education and support through personalized interactions, help patients adjust to the use of their medicine, and in many programs, also provide lifestyle management support to further promote health.

Outside the US, our AbbVie Care program includes a wide range of disease- and country-specific patient programs that provide meaningful, informative and empowering support to patients who have been prescribed AbbVie medicines. These programs are tailored to the needs and regulations in each country and patient community.

AbbVie personnel do not give medical advice and are trained to direct patients to their health care professional for any treatment-related questions.